AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the appointment of Greg Madison as executive vice president and chief commercial officer. Mr. Madison brings a wealth of hands-on commercial experience and extensive leadership skills to AMAG. He joins AMAG from Genzyme Corporation, where he spent the past 12 years in various commercial roles in their renal division, most recently as the division’s vice president and general manager.
“Through his distinguished career at Genzyme, Greg has had the opportunity to lead almost every commercial function relevant to buy-and-bill products, which makes him uniquely qualified to lead the commercial team at AMAG and drive the continued growth of Feraheme®,” said William Heiden, president and chief executive officer of AMAG. “His experience in the chronic kidney disease (CKD) market will help us identify new ways to drive growth of Feraheme within our current indication.”
Heiden continued, “Additionally, Greg has driven the strategy development, planning and execution of several product launches – this experience will be invaluable to AMAG as we prepare for the potential regulatory approval of Feraheme for the treatment of iron deficiency anemia in a broader patient population. We will also benefit from Greg’s broad experience in our business development efforts, as he will play a key role in the evaluation and the commercialization of new acquired or in-licensed assets in the future. We are really pleased to welcome Greg to AMAG.”
Since joining Genzyme in 2000, Mr. Madison developed extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as vice president and general manager for the renal division. In this role, Mr. Madison led a global organization with three marketed products in 76 countries and drove top-line growth, with combined revenues exceeding $1 billion. Mr. Madison’s prior experience in the division includes serving as vice president and general manager of the U.S. business; vice president of U.S. sales; and vice president of U.S. marketing where he led all pre-launch preparation for Renvela, now the leading phosphate binder in the U.S. market. During his tenure with Genzyme, Mr. Madison also had roles in sales management, training, and managed markets and reimbursement. Prior to joining Genzyme, Mr. Madison spent five years at Jannsen Pharmaceuticals in sales and sales management roles, and began his career in the pharmaceutical industry in sales with Wyeth-Ayerst.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV